{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:08:45Z","timestamp":1785528525996,"version":"3.56.0"},"reference-count":40,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ABL Bio Inc., Republic of Korea","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,9,15]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) is a type of leukemia in adults with a high mortality rate and poor prognosis. Although targeted therapeutics, chemotherapy, and hematopoietic stem cell transplantation can improve the prognosis, the recurrence rate is still high, with a 5-year survival rate of approximately 40%. This study aimed to develop an IgG-based asymmetric bispecific antibody that targets CLL-1 and CD3 for treating AML.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>ABL602 candidates were compared in terms of binding activity, T-cell activation, and tumor-killing activities. ABL602-mediated T-cell activation and tumor-killing activities were determined by measuring the expression of activation markers, cytokines, cytolytic proteins, and the proportion of dead cells. We evaluated in vivo tumor growth inhibitory activity in two mouse models bearing subcutaneously and orthotopically engrafted human AML. Direct tumor-killing activity and T-cell activation in patient-derived AML blasts were also evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ABL602 2+1 showed a limited CD3 binding in the absence of CLL-1, suggesting that steric hindrance on the CD3 binding arm could reduce CLL-1 expression-independent CD3 binding. Although the CD3 binding activity was attenuated compared with that of 1+1, ABL602 2+1 exhibited much stronger T-cell activation and potent tumor-killing activities in AML cell lines. ABL602 2+1 efficiently inhibited tumor progression in subcutaneously and orthotopically engrafted AML mouse models. In the orthotopic mouse model, tumor growth inhibition was observed by gross measurement of luciferase activity, as well as a reduced proportion of AML blasts in the bone marrow, as determined by flow cytometry and immunohistochemistry (IHC) staining. ABL602 2+1 efficiently activated T cells and induced the lysis of AML blasts, even at very low effector:target (E:T) ratios (eg, 1:50). Compared with the reference 1+1 antibody, ABL602 did not induce the release of cytokines including interleukin-6 and tumor necrosis factor-\u03b1 in the healthy donor-derived peripheral blood mononuclear cell.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>With its potent tumor-killing activity and reduced cytokine release, ABL602 2+1 is a promising candidate for treating patients with AML and warrants further study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007494","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:45:41Z","timestamp":1697543141000},"page":"e007494","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Asymmetric anti-CLL-1\u00d7CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0929-8697","authenticated-orcid":false,"given":"Eunhee","family":"Lee","sequence":"first","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinai","family":"Lee","sequence":"additional","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumyeong","family":"Park","sequence":"additional","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Gyu","family":"Son","sequence":"additional","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiseon","family":"Yoo","sequence":"additional","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Jongno-gu, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Jongno-gu, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmi","family":"Lim","sequence":"additional","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghwa","family":"Won","sequence":"additional","affiliation":[{"name":"ABL Bio Inc, Seongnam, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2025100314142788000_11.10.e007494.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129204"},{"key":"2025100314142788000_11.10.e007494.2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063304","article-title":"Increasing role of targeted immunotherapies in the treatment of AML","volume":"23","author":"Greiner","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025100314142788000_11.10.e007494.3","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101224","article-title":"Cd33 directed Bispecific antibodies in acute myeloid leukemia","volume":"33","author":"Clark","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025100314142788000_11.10.e007494.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100314142788000_11.10.e007494.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100314142788000_11.10.e007494.6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"2025100314142788000_11.10.e007494.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"2025100314142788000_11.10.e007494.8","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.35","article-title":"Acute myeloid leukemia targets for bispecific antibodies","volume":"7","author":"Hoseini","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025100314142788000_11.10.e007494.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1011"},{"key":"2025100314142788000_11.10.e007494.10","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-109762","article-title":"A phase 1 first-in-human study of Amg330, an anti-Cd33 Bispecific T-cell engager (bite) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"2025100314142788000_11.10.e007494.11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a Cd123\/Cd3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025100314142788000_11.10.e007494.12","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1080\/21645515.2020.1788299","article-title":"Targeting the alpha subunit of IL-3 receptor (Cd123) in patients with acute leukemia","volume":"16","author":"Aldoss","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"2025100314142788000_11.10.e007494.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0180-3"},{"key":"2025100314142788000_11.10.e007494.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1659"},{"key":"2025100314142788000_11.10.e007494.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.10.003"},{"key":"2025100314142788000_11.10.e007494.16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00446","article-title":"Perspective: designing T-cell Engagers with better therapeutic windows","volume":"10","author":"Vafa","year":"2020","journal-title":"Front Oncol"},{"key":"2025100314142788000_11.10.e007494.17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with Cd3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"2025100314142788000_11.10.e007494.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001"},{"key":"2025100314142788000_11.10.e007494.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"2025100314142788000_11.10.e007494.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by Cd3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"2025100314142788000_11.10.e007494.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002444","article-title":"Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies","volume":"9","author":"Poussin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100314142788000_11.10.e007494.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002488","article-title":"Attenuating Cd3 affinity in a Psmaxcd3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"9","author":"Dang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100314142788000_11.10.e007494.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003616","article-title":"Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of Her3-expressing cancer cells independent of cytokine release","volume":"9","author":"Aschmoneit","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100314142788000_11.10.e007494.24","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1574521"},{"key":"2025100314142788000_11.10.e007494.25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","article-title":"MCLA-117, a Clec12Axcd3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis","volume":"19","author":"van Loo","year":"2019","journal-title":"Expert Opinion on Biological Therapy"},{"key":"2025100314142788000_11.10.e007494.26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/bloodadvances.2019001188","article-title":"A novel C2 domain binding Cd33Xcd3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia","volume":"4","author":"Nair-Gupta","year":"2020","journal-title":"Blood Adv"},{"key":"2025100314142788000_11.10.e007494.27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-Her2\/Cd3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"key":"2025100314142788000_11.10.e007494.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2018.10.026"},{"key":"2025100314142788000_11.10.e007494.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-735365"},{"key":"2025100314142788000_11.10.e007494.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"2025100314142788000_11.10.e007494.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"2025100314142788000_11.10.e007494.32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5775","article-title":"Avidity-based binding to Her2 results in selective killing of Her2-overexpressing cells by anti-Her2\/Cd3","volume":"10","author":"Slaga","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100314142788000_11.10.e007494.33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2025100314142788000_11.10.e007494.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2622"},{"key":"2025100314142788000_11.10.e007494.35","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030399","article-title":"A novel T cell-engaging bispecific antibody for treating mesothelin-positive solid tumors","volume":"10","author":"Yoon","year":"2020","journal-title":"Biomolecules"},{"key":"2025100314142788000_11.10.e007494.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501592"},{"key":"2025100314142788000_11.10.e007494.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01253-x"},{"key":"2025100314142788000_11.10.e007494.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241091","article-title":"Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody Cd20-TCB induces IFN\u03b3\/Cxcl10-dependent peripheral T cell recruitment in humanized murine model","volume":"16","author":"Cremasco","year":"2021","journal-title":"PLOS ONE"},{"key":"2025100314142788000_11.10.e007494.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2334336100"},{"key":"2025100314142788000_11.10.e007494.40","doi-asserted-by":"publisher","DOI":"10.1038\/ni1058"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:14:35Z","timestamp":1759526075000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/jitc-2023-007494"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007494","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}